Acute pancreatitis in children – morbidity and outcomes at 1 year

A Bhanot,1 AA Majbar,2 Toby Candler,3,4 LP Hunt,4 E Cusick,5 Paul R V Johnson,6,7 Julian PH Shield6,3,4

ABSTRACT

Objective To establish short-term and medium-term complications 1-year postdiagnosis, of acute pancreatitis (AP) in children aged 0–14 years.

Design One-year follow-up of a prospective monthly surveillance of new cases of AP in children under 15 years through the British Paediatric Surveillance Unit (BPSU) from April 2013 to April 2014.

Setting A monthly surveillance of >3700 consultant paediatricians and paediatric surgeons in the UK and Ireland using the BPSU.

Patients Children aged 0–14 years with a new diagnosis of AP.

Main outcome measures The outcomes following AP, including the incidence of complications and comorbidity at diagnosis and at 1 year.

Results Of the 94 new confirmed cases of AP identified in the UK during the study period, 90 cases (96%) were included in the 1-year follow-up. 30 patients (32%) developed further episode(s) of AP. Over one-fifth of patients developed one or more major complication. At initial admission, the most common of these was pancreatic necrosis (n=8, 9%), followed by respiratory failure (n=7, 7%). Reported complications by 1 year were pseudocyst formation (n=9, 10%), diabetes requiring insulin therapy (n=4, 4%) and maldigestion (n=1, 1%). At 1-year postdiagnosis, only 59% of children made a full recovery with no acute or chronic complications or recurrent episodes of AP. Two patients died, indicating a case fatality of ~2.0%.

Conclusions AP in childhood is associated with significant short-term and medium-term complications and comorbidities including risk of recurrence in approximately a third of cases.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ The clinical course and complications of acute pancreatitis (AP) in children are variable, ranging from mild self-limiting illness to organ failure and death.
⇒ Following an episode of AP, children may develop further episodes.
⇒ There has been no prospective study focusing on the complications and morbidities following AP in children and the incidence of these complications.

WHAT THIS STUDY ADDS

⇒ The most common complications of AP were pancreatic necrosis initially and in the medium term, pseudocyst formation and diabetes requiring insulin.
⇒ Following AP, a significant minority of children will not make a full recovery without residual problems.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Even if classified as mild, childhood AP can lead to significant complications and morbidities and should not be considered a benign condition in childhood.

INTRODUCTION

Acute pancreatitis (AP) is an inflammatory condition classically presenting with sudden-onset upper abdominal pain.1 Our previous prospective study found an incidence of AP in UK children under 15 years of 0.78 per 100,000.2 It is reported that 25% of children develop major complications following an episode of AP.3,4 The clinical course and complications of AP in children are variable, ranging from mild self-limiting illness to organ failure and death.5,6 Pancreatic necrosis, pseudocyst formation and abscesses are some of the complications following AP.9 Diabetes mellitus (DM) after AP has also been reported in children, with one retrospective study in the USA reporting DM in 4.5% of cases.7 Until now in the UK, there has been no prospective study focusing on the complications and comorbidity following AP in children.

Following an episode of AP, children may develop further episodes.8 Recurrence has been reported in 15%–35% of children with AP.8 One prospective study in the USA found that 17% of patients developed acute recurrent pancreatitis following an episode of AP.8 However, the rate of recurrence following AP has yet to be determined in a prospective UK study.

The aim of this study was to conduct a prospective follow-up to our previous national-based analysis of AP in childhood to characterise the outcomes of AP, including determining the prevalence of complications and co-morbidity in the short to medium term.

METHODS

As previously described, a prospective study was carried out using the British Paediatric Surveillance Unit (BPSU) reporting system
of the Royal College of Paediatrics and Child Health (RCPCH) to identify any new diagnosis of AP in children aged 0–14 years old in the UK and Ireland. From April 2013 to April 2014, AP in children under the age of 15 years was included on the orange card sent monthly to all consultant paediatricians who undertake clinical work in the UK or the Ireland. To identify children directly referred to surgical departments, the British Association of Paediatric Surgeons (BAPS) supported this study and paediatric surgeons received the orange card during the study period.

Diagnosis of AP required at least two of the three following features: (1) Acute onset of upper abdominal pain; (2) Serum amylase and/or lipase raised ≥3 times the upper limit of normal local range and (3) Imaging findings characteristic of AP. These criteria for the diagnosis of AP were adapted according to revised Atlanta criteria by the ‘Acute Pancreatitis Classification Working Group’ and a consensus of the International Study Group of Paediatric Pancreatitis: In Search for a Cure. Clinicians returned the card notifying the BPSU of any AP cases seen or ‘nothing to report’. The orange card return compliance was 95.3% during the study.

Each reporting clinician was sent an initial questionnaire to collect additional information on the clinical presentation, diagnosis and management, as well as acute complications and mortality. On the questionnaire’s completion, the eligibility of the patient was determined and the physicians’ diagnoses were reviewed by the study investigators (AAM, JPHS and EC). If a child had more than one episode of AP during the study period, only the first episode was included as a new case and the information on following episode(s) was used as follow-up data.

A second questionnaire was sent to the reporting clinician 1 year after the initial presentation for diagnostic review, establish management pattern, and identify associated morbidity and outcome. The follow-up questionnaire had four sections. Section A collected information about weight and height. Section B collected data on medium term complications. Section B1 asked about any new surgical interventions, as well as development of pseudocyst, its diagnosis and treatment. Section B2 asked about the development of diabetes, and/or maldevelopment and its diagnosis and treatment. Section C detailed further investigations undertaken after initial investigation and Section D asked about recurrence and outcome. The initial questionnaire also collected data on acute complications and mortality.

Statistics
Data were analysed using the SPSS (V.21.0, IBM), Stata V.12.1 (StataCorp) and Microsoft Excel (2013).

The proportions of patients who were considered to have mild or moderate/severe disease were determined. Factors associated with developing AP were compared between mild and moderate/severe groups using Fisher’s exact test.

The percentages of patients developing short-term and medium-term complications up to 1 year postdiagnosis of the first episode of AP were determined. Criteria for considering major complications of the first episode were: (1) all complications required to classify an episode as moderate/severe pancreatitis (organ failure, pancreatic necrosis, and pseudocyst formation), (2) complications requiring treatment at the initial admission (hyperglycaemia) and (3) residual disorders requiring treatment at the end of the follow-up period (diabetes and maldevelopment). The major complications were divided into short term (identified early during initial admission) and medium term (identified in patients with prolonged admission or after discharge during follow-up). Minor complications were also reported.

The percentage of patients who developed further episode(s) of AP within 1 year from diagnosis were identified, as well as the average number of recurrent episodes and reported associations.

Results
From April 2013 to April 2014, there were 94 new confirmed cases of AP identified. At 1-year follow-up, clinical data were available for 90 of these cases (96%), no responses were received for four cases (figure 1).

Demographics
Female to male ratio was equal with 48/94 (51%) male. The median age at diagnosis was 11.2 years (IQR 7.1–14.4), range 1.3–14.9 years. White children accounted for 57 of 94 cases (61%), compared with 26 (28%) from Asian and 5 (5%) from African ethnic groups. Children of Pakistani origin accounted for the majority (18 of 26; 69%) of the patients of Asian heritage and 19% of the total cohort.

Outcomes
Sixteen (17%) of the 94 new cases were considered to have moderate/severe disease. There was no association found between aetiology of AP and disease severity (p=0.22, table 1). Two children (2.1%) died in hospital during their first admission: both had underlying chronic conditions (propionic acidemia and cerebral palsy, global developmental delay, epilepsy and microcephaly). All children required hospital management; eight requiring intensive care. Eighty-six patients (91%) were treated conservatively during their initial hospitalisation. Twenty (21%) required one or more related surgical intervention during the initial admission and/or
the follow-up period. The most common indications for surgical intervention were: diagnostic laparoscopies in seemingly idiopathic cases, elimination of the underlying predisposing factors such as gallstones and choledochal cysts, and treatment of complications (table 2).

The outcomes of the 90 cases included at 1 year are shown in table 3. Residual comorbidities included

### Table 1  Main associations of acute pancreatitis in severe and mild cases

<table>
<thead>
<tr>
<th>Main association</th>
<th>Severity</th>
<th>Moderate/severe (n=16) No of cases (%)</th>
<th>Mild (n=78) No of cases (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Idiopathic</td>
<td></td>
<td>4 (25)</td>
<td>31 (40)</td>
</tr>
<tr>
<td>Drugs</td>
<td></td>
<td>6 (38)</td>
<td>12 (15)</td>
</tr>
<tr>
<td>Gallstones</td>
<td></td>
<td>1 (6)</td>
<td>11 (14)</td>
</tr>
<tr>
<td>Hereditary</td>
<td></td>
<td>1 (6)</td>
<td>6 (8)</td>
</tr>
<tr>
<td>Organic acidemia</td>
<td></td>
<td>2 (13)</td>
<td>5 (6)</td>
</tr>
<tr>
<td>Anatomical anomalies</td>
<td></td>
<td>.</td>
<td>5 (6)</td>
</tr>
<tr>
<td>Viral infections</td>
<td></td>
<td>1 (6)</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Systemic diseases</td>
<td></td>
<td>.</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Trauma</td>
<td></td>
<td>1 (6)</td>
<td>.</td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td>.</td>
<td>4 (5)</td>
</tr>
</tbody>
</table>

*Intervention during the follow-up period.
†Intervention at initial admission.
CBD, common bile duct; ERCP, endoscopic retrograde cholangiopancreatography.

### Table 2  Surgical and interventional procedures performed in 20 patients

<table>
<thead>
<tr>
<th>No</th>
<th>Gender, age (years)</th>
<th>Association</th>
<th>Intervention(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male, 2.3</td>
<td>Methylmalonic acidemia</td>
<td>1. ERCP sphincterotomy*</td>
</tr>
<tr>
<td>2</td>
<td>Female, 12.6</td>
<td>Gallstones</td>
<td>1. ERCP sphincterotomy and stones removal* 2. Elective cholecystectomy*</td>
</tr>
<tr>
<td>3</td>
<td>Male, 13</td>
<td>Gallstones</td>
<td>1. Elective cholecystectomy*</td>
</tr>
<tr>
<td>4</td>
<td>Female, 13.7</td>
<td>Pancreas divisum</td>
<td>1. ERCP, pancreatic duct drainage, sphincterotomy and stent insertion*</td>
</tr>
<tr>
<td>5</td>
<td>Male, 14.1</td>
<td>Sodium valproate</td>
<td>1. Percutaneous drainage of Left sided abdominal collection*</td>
</tr>
<tr>
<td>6</td>
<td>Male, 14.8</td>
<td>Gallstones</td>
<td>1. Laparoscopic cholecystectomy†</td>
</tr>
<tr>
<td>7</td>
<td>Female, 8</td>
<td>Choledochal cyst</td>
<td>1. Excision of type I fusiform choledochal malformation*</td>
</tr>
<tr>
<td>8</td>
<td>Male, 4.9</td>
<td>Idiopathic</td>
<td>1. ERCP, cyst-duodenostomy stent (Stent removed)*</td>
</tr>
<tr>
<td>9</td>
<td>Male, 10.3</td>
<td>Trauma</td>
<td>1. Endoscopic stent for pseudocyst† (unsuccessful) 2. Laparoscopic cystgastrostomy for pseudocyst†</td>
</tr>
<tr>
<td>10</td>
<td>Female, 13.5</td>
<td>Gallstones</td>
<td>1. Elective laparoscopic cholecystectomy*</td>
</tr>
<tr>
<td>11</td>
<td>Male, 2</td>
<td>Asparaginase</td>
<td>1. Diagnostic laparoscopy†</td>
</tr>
<tr>
<td>12</td>
<td>Female, 14.8</td>
<td>Gallstones</td>
<td>1. Elective cholecystectomy*</td>
</tr>
<tr>
<td>13</td>
<td>Female, 13.5</td>
<td>Gallstones</td>
<td>1. Cholecystectomy and Splenectomy*</td>
</tr>
<tr>
<td>14</td>
<td>Male, 14.6</td>
<td>Gallstones</td>
<td>1. ERCP sphincterotomy and stones removal† 2. Laparoscopic cholecystectomy*</td>
</tr>
<tr>
<td>15</td>
<td>Male, 5.5</td>
<td>Choledochal cyst</td>
<td>1. Excision of choledochal malformation with hepaticojunostomy*</td>
</tr>
<tr>
<td>16</td>
<td>Female, 12</td>
<td>Viral infection</td>
<td>1. Laparotomy and drainage of large peripancreatic collection in lesser sac†</td>
</tr>
<tr>
<td>17</td>
<td>Male, 5.4</td>
<td>Hereditary</td>
<td>1. ERCP and stent placement† 2. ERCP and stent removal†</td>
</tr>
<tr>
<td>18</td>
<td>Female, 12</td>
<td>Idiopathic</td>
<td>1. Diagnostic laparoscopy for acute abdomen†</td>
</tr>
<tr>
<td>19</td>
<td>Male, 14.7</td>
<td>Gallstones</td>
<td>1. Elective laparoscopic cholecystectomy*</td>
</tr>
<tr>
<td>20</td>
<td>Male, 14.6</td>
<td>Gallstones</td>
<td>1. ERCP and removal of 6 CBD stones†</td>
</tr>
</tbody>
</table>

*Intervention during the follow-up period.
†Intervention at initial admission.
insulin-dependent diabetes (n=4), clinical and imaging features of chronic pancreatitis (n=3), mal-digestion with failure to thrive (n=1) and residual radiological changes in the pancreas without significant clinical findings (n=1).

**Recurrent disease**

Thirty patients (33%) developed further episode(s) of AP within 1 year. These 30 had 88 episodes during the study period with an average of 2.9 episodes/patient (table 4). Twenty-five of these (83%) had mild initial episodes.

The reported aetiology of AP in the recurrent group were idiopathic (n=13, 43%), genetic (n=5, 17%), drugs (n=5, 17%), organic acidaemias (n=4, 13%), pancreas divisum (n=1, 3%), gallstones (n=1, 3%) and α1-antitrypsin deficiency (n=1, 3%). Each of the five drug-associated cases (two asparaginase, one mercaptopurine, one carbamazepine and one opiates) developed one further episode. The recurrent episode in the child whose first episode was due to opiates was again attributed to opiates. The new episode in the child whose first episode was mercaptopurine-associated was ascribed to prednisolone treatment for acute lymphoblastic leukaemia. For the other three cases, available data did not confirm or discount whether the new episodes developed by re-introducing the same medication.

At least one imaging examination was performed during the first episode in the majority of this recurrent group (28 of 30; 93%). Further investigations, including imaging examinations and/or genetic testing, were performed for 22 of the 30 recurrent cases (73%). The genetic and α1-antitrypsin deficiency cases were identified by additional investigations after developing further episode(s). Apart from organic acidaemia cases, all cases with ≥2 recurrent episodes underwent one or more further investigation to exclude possible underlying aetiologies.

<table>
<thead>
<tr>
<th>Table 4</th>
<th>Number of episodes of acute pancreatitis in the 30 patients who had a recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of episodes</td>
<td>No of children (%)</td>
</tr>
<tr>
<td>2</td>
<td>17 (57)</td>
</tr>
<tr>
<td>3</td>
<td>4 (13)</td>
</tr>
<tr>
<td>4</td>
<td>4 (13)</td>
</tr>
<tr>
<td>5</td>
<td>4 (13)</td>
</tr>
<tr>
<td>6</td>
<td>1 (3)</td>
</tr>
</tbody>
</table>

**Table 5** Major reported complications of acute pancreatitis

<table>
<thead>
<tr>
<th>Complication</th>
<th>No of cases* (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short term (at initial admission, n=94)</td>
<td></td>
</tr>
<tr>
<td>Pancreatic necrosis</td>
<td>8 (9)</td>
</tr>
<tr>
<td>Respiratory failure</td>
<td>7 (7)</td>
</tr>
<tr>
<td>Hyperglycaemia required insulin therapy</td>
<td>6 (6)</td>
</tr>
<tr>
<td>Circulatory collapse</td>
<td>4 (4)</td>
</tr>
<tr>
<td>Renal failure</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Gastrointestinal bleeding</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Medium term (n=90)</td>
<td></td>
</tr>
<tr>
<td>Pseudocyst formation</td>
<td>9 (10)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>4 (4)</td>
</tr>
<tr>
<td>Mal-digestion</td>
<td>1 (1)</td>
</tr>
</tbody>
</table>

*Some patients had more than one complication.

Genetic screening for SPINK1 (serine peptidase inhibitor, Kazal type 1), PRSS1 (cationic trypsinogen gene) and CFTR (cystic fibrosis transmembrane conductance regulator) gene mutations was performed for 12 of 30 cases with recurrent AP (40%). Of those who had genetic testing, five tests were positive (42%): three SPINK1 and two PRSS1 mutations. Additional imaging identified one case of pancreas divisum. The gallstone-associated case was diagnosed at the first episode, the patient developing a further episode while awaiting surgery. Three children of the 30 with recurrence (10%) showed imaging and clinical signs of chronic pancreatitis.

**Major complications**

Acute or within 1 year, 21/90 children (23%) developed one or more major complication (table 5). Some children developed more than one: one with five complications, four having four, one had three and five had two. Ten children developed one major complication. If recurrence were added as a significant AP complication, the number developing complications would increase to 45 of 90 children (50%).

The most common significant complication reported at initial admission was pancreatic necrosis in eight (9%). The aetiological associations of AP in pancreatic necrosis cases were idiopathic (n=3), medication (two asparaginase, one sodium valproate-associated), gallstones (n=1) and viral (n=1). Three of these eight cases required intensive care therapy. All cases, except one, were treated conservatively. One child died within 10 hours of admission to paediatric intensive care unit without surgical intervention.

Other major complications included respiratory failure in seven (7%), hyperglycaemia which required insulin therapy at some stage in six (6%), circulatory collapse in four (4%), renal failure in two (2%), and gastrointestinal bleeding in two (2%).

The main reported medium-term complications were pseudocyst formation (n=9, 10%), diabetes requiring insulin therapy at 1 year (n=4, 4%) and mal-digestion.
(n=1, 1%). The aetiopathological associations of AP in the
nine pseudocyst cases were drug therapy (n=4) and one
each for trauma, gallstones, propionic acidaemia, viral
infection and idiopathic. Six of nine pseudocysts sponta-
neously resolved during follow-up; two had incomplete
follow-up data and one required surgical intervention.
One of the diabetes cases had no reported hyperglyca-
emia initially. The case of malnutrition was diagnosed by
both abnormal stool elastase and failure to thrive.

Additional reported acute complications were hyperglyca-
emia (n=23, 24%), hypoalbuminaemia (n=49, 52%),
moderate amounts of free fluid collection in the abdomen
(n=28, 30%), pleural effusion (n=13, 14%), lung consoli-
dation (n=3, 3%), lung collapse (one case), deterioration
of pre-existing renal dysfunction (n=2, 2%), superior
mesenteric vein thrombosis (n=1, 1%) and decompensa-
tion of propionic acidaemia (n=1, 1%). Increased seized
activity developed in a child taken off sodium valproate.
An episode of AP altered future planned chemotherapy
treatment for all children with leukaemia.

**DISCUSSION**

This study demonstrates that AP associates with significant
morbidity in the short and medium term carrying a small
but significant mortality risk. Other than recurrence, over
one-fifth of patients develop one or more significant compli-
cations. This recapitulates the 20%–25% reported in other
previous paediatric studies. As in several previous studies,
pseudocyst formation was the most common major compli-
cation, identified in 10% in this current study, the majority
of which resolved spontaneously within 1 year.

Pancreatic necrosis, organ failure and hyperglycaemia
requiring insulin treatment are the most frequent signifi-
cant complications at first admission. In this study,
pancreatic necrosis was reported in 9% of cases which was
more than the 4.0% reported by Fonseca Sepúlveda and
Guerrero-Lozano. This study also shows that pancreatic
 necrosis may occur with variable aetiopathological associa-
tions in agreement with Raizner et al. Transient hyperglycaemia is
quite frequent in children with AP, with six requiring insulin
therapy in hospital. Four children (4%) developed diabetes
requiring regular insulin treatment at 1 year. This figure is
similar to the 4.5% reported by a retrospective study from
the United States but less than the 8% reported in a previous
UK study.

Within the follow-up period, one child with methylma-
-lonic acidaemia developed malabsorption and failure to thrive
following a first mild episode of AP. However, reporting
of only one patient with pancreatic exocrine insufficiency
(PEI) is likely to be a significant underestimate, as several
patients had endocrine insufficiency at diagnosis and 1 year
later. In adults, it has been found that PEI occurs frequently
in individuals recovering from severe AP. Studies suggest
an absence of clinical symptoms does not allow the predic-
tion of a normal nutritional status or sufficient treatment in
chronic pancreatitis patients. Therefore, routine evalua-
tion of exocrine pancreatic function using faecal elastase-1
is recommended after all cases of AP to detect any PEI and
provide guidance in decisions on enzyme replacement
therapy.

This study also shows that hypocalcaemia is common
acutely, particularly in severe cases, consistent with other
reports. No cases required treatment. Other common
abnormalities not requiring specific interventions were
hypalbuminaemia (52%), abdominal free fluid collect-
tions (30%) and pleural effusions (14%). Future research
may benefit from focusing on these common abnormal-
ities and particularly their roles in the prediction of AP
severity.

Recurrent pancreatitis is a problem following the first
diagnosis of AP. One third of children developed recurrent
episode(s) within 1 year, which is comparable to the 28% reported
in Italy, 33% in Canada and 36% in Mexico. However, it is higher than the 10% previously reported in
Scotland, likely due to the significant change in the aetio-
logical associations of AP in childhood, and also higher than
the 17% reported from the USA. 

Idiopathic (43%), hereditary factors (17%), medica-
tion (17%) and organic acidaemias (13%) are the the
most common associations of acute recurrent pancreatitis,
similar to findings in other studies. Some of the idio-
pathic cases may represent under-investigation for genetic
or autoimmune causation. This study found relapse may
follow both mild and moderate/severe initial AP episodes.
However, the majority (83%) of patients who developed
recurrence had mild first episodes. When combining both
complications and recurrence, 50% (45/90) of the patients
in this study developed either major complication(s) from
the first episode and/or recurrent pancreatitis within a year
from diagnosis. The high recurrence rate with AP observed
in this study and several previous paediatric series suggests
AP is not a benign disease, even if classified initially as
mild.

Two patients died which indicates that AP has a case
fatality of ~2.0% in the UK. This is less than the 5.3% and
6.3% reported in two earlier UK series. Case fatality
figures correspond to the 2% reported by a Scottish
report being in line with a review suggesting mortality
is less than 5% in most cohorts. It is noticeably lower
than the 10% reported in adults.

A study limitation was the possibility that diabetes in some
cases was the result of a contemporaneous onset of autoim-
mune type 1 diabetes but data on antibody status was not
collected in the survey. Reporting of this follow-up paper
was delayed due to the lead researcher being caught up in
civil conflict, but we believe the data interpretation is still
robust. Patients were reported by paediatricians or paedi-
atrie surgeons who are members of BAPS. We believe that
the vast majority of cases in those <15 years will have been
managed by these professionals. However, there may be a
small proportion of patients who are managed solely by adult
surgeons (or paediatric surgeons who are not members
of BAPS) and would therefore be missed from reporting.
Furthermore, a degree of under-reporting is likely with any
voluntary surveillance system.
In summary, this study suggests that AP is associated with significant medium-term morbidity. One year after diagnosis, only 59% of children made a full recovery with no acute or chronic complications or recurrent episodes of AP. Recurrence and/or other complications were experienced by 41% of patients. Residual comorbidities were identified in about 1/10th of children. Even if classified initially as a mild episode, the prognosis for AP should be guarded.

Acknowledgements  We need to acknowledge the significant contribution of Mr Richard Lynn, late of the RCHP BPSU to the successful running of this study. This is an independent opinion from Bristol Biomedical Research Centre in the National Institute for Health Research Biomedical Research Centre and Unit Funding Scheme.

Contributors  AB wrote the preliminary draft paper under supervision from TC, AAM conducted the BPSU study and performed the data analyses, JPH developed the mechanics of the study and is the study guarantor, LPH supported and advised on the development of the study, PRVJ edited the questionnaires and contributed to the statistical analysis, EC and PRVJ edited the questionnaires and contributed to the final editing.

Funding  This study was funded by the Libyan Ministry of Higher Education and Scientific Research represented by the Libyan Embassy in London as an MD scholarship for Dr A Majbar at the University of Bristol. Additional funding came from the National Institute for Health Research Biomedical Research Centre Funding Scheme.

Disclaimer  The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

Competing interests  No, there are no competing interests.

Patient and public involvement  Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication  Not applicable.

Ethics approval  The study was approved by the National Research Ethics Service Committee South West, Central Bristol (REC reference 11/SW/0132) and was granted Section 251 of the National Information Governance Board for Health and Social Care permission by its Ethics and Confidentiality Committee under reference ECC 6-022/F12/2012.

Provenance and peer review  Not commissioned; externally peer reviewed.

Data availability statement  Data may be obtained from a third party and are not publicly available.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 United States (CC BY 4.0) licence, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/

ORCID iDs  
Toby Candler http://orcid.org/0000-0002-4587-8744
Julian PH Shield http://orcid.org/0000-0003-2601-7575

REFERENCES


bmjpo: first published as 10.1136/bmjpo-2022-001487 on 5 July 2022. Downloaded from bmjpo.sagepub.com/ by guest. Protected by copyright.